🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

☑️#ASCO25 Abstract🆙 ☑️#LCSM Poster 🔥DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results 🎙️ Dr. Martin Wermke 📌Poster Bd215, Abstr 8094 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

☑️#ASCO25 Abstract🆙 ☑️#LCSM Poster 🔥Results of a phase 1 study of LB2102, a dnTGFβRII armored DLL3-targeted autologous CAR-T cell therapy, in pts with relapsed or refractory SCLC and LCNEC 🎙️ Jacob sands 📌Poster Bd225, Abstr 8104 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

DLL3 is highly expressed in SCLC and is a key target for new therapies. Here is a comparative overview of early-stage products across different modalities at ASCO 2025. Be the first to know the latest from #ASCO25: t.ly/7TCD6 #LARVOL #ASCO2025 #LungCancer #SCLC

☑️#ASCO25 Abstract🆙 ☑️#LCSM Oral, Mets 🔥HERTHENA-Lung02: Patritumab deruxtecan (HER3-DXd) in resistant EGFR-m NSCLC after a 3rd-gen EGFR TKI 🎙️ Tony Mok 🎯PFS HR 0.77 (95%CI 0.63-0.94), mPFS HER3-DXd vs PBC 5.8 vs 5.4m OncoAlert ASCO meetings.asco.org/2025-asco-annu…

🆕JUST IN🆙 🌧️Voluntarily Withdrawn 💉Patritumab Deruxtecan (HER3-DXd) 🎯OS did not meet statistical significance 🎙️ U.S. FDA Merck merck.com/news/patrituma… #LCSM OncoAlert LARVOL

🆕JUST IN🆙 🔥HARMONi positive PFS, positive trends in OS 💉Ivonescimab (SMT112, AK112): PD-1 x VEGF 🎯PFS HR 0.52 (95%CI: 0.41-0.66), statistically positive 🎯OS HR 0.79 (95%CI: 0.62-1.01),primary analysis 🎙️ Summit Therapeutics smmttx.com/pressrelease/h… #LCSM OncoAlert LARVOL

Here are the top diagnostics from the ASCO 2025 abstracts. Follow us and get the latest #ASCO25 updates: t.ly/7TCD6 #LARVOL #ASCO2025 #Oncology #CancerResearch #CancerData #OncologyInsights #CancerCare | LARVOL | Matteo Lambertini, MD PhD | Mark Lewis, MD, FASCO | Vivek Subbiah, MD |

The #OncoAlertTopTweet 🚨Day One #ASCO25 Give it a whirl at👉my.medical.watch/oncoalert/hash… #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Bárbara Melão, MD, PhD

🆕 #ASCO25 🆙 ☑️Developmental Tx, Oral 🔥BL-B01D1: EGFR x HER3 bispecific ADC in pts with NSCLC with driver genomic alterations 🎙️ Dr. Yunpeng Yang 🎯ORR: EGFR ex20ins 69.2%, HER2 52.9%, ALK/ROS1/RET 34.8%, KRAS/BRAF/MET 40.0% OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️Developmental Tx, Oral 🔥MONSTAR-SCREEN-3: Ultra-sensitive pan-cancer #MRD assessment using whole-genome sequencing-based personalized ctDNA panel 🎙️ Dr. Tadayoshi Hashimoto 🎯100% baseline sensitivity (41/41) OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️Developmental Tx, Oral 🔥BL-B01D1: EGFR x HER3 bispecific ADC in pts with SCLC 🎙️ Dr. Yan Huang 🎯Overall: ORR 48.1%, PFS 4.1m, OS 12.2m 🎯Post-Chemo ICI: ORR 75%, PFS 6.9m, OS 15.0m OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

🚨 Early registration is OPEN for #ACLC2025! 🌏 Tackling lung cancer across Asia: detection, AI, disparities, and innovation. 🗓️ Abstracts due by July 10! Join us in advancing thoracic oncology. 🔗 bit.ly/ACLC25 #IASLC #LungCancer #Oncology #CancerResearch

🆕 #ASCO25 🆙 ☑️Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non–Small Cell Lung Cancer 🔥Let's Talk Toxicity 🎙️Dr. Jessica R. Bauman 🎯The Role of Shared Decision-Making in Front-Line Treatment Selection OncoAlert ASCO EGFR Resisters meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non–Small Cell Lung Cancer 🔥DEBATE Julia Rotow MD 🆚 Alessio Cortellini 🔥DEBATE Osimertinib Mono 🆚 Combination (MARIPOSA/FLAURA2) OncoAlert ASCO EGFR Resisters meetings.asco.org/2025-asco-annu…

🆕 #ASCO25 🆙 ☑️Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non–Small Cell Lung Cancer 🔥Osimertinib Alone as Front-Line Therapy 🎙️ Julia Rotow MD OncoAlert ASCO EGFR Resisters meetings.asco.org/2025-asco-annu…

#HearHer is at #ASCO25 - n=200 ONLY Stop me ✋ or #FlorezLab team for yours Because lung cancer is a disease of WOMEN Young Lung Cancer Initiative OncoAlert Oncology Brothers ASCO

🆕 #ASCO25 🆙 ☑️Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non–Small Cell Lung Cancer 🔥Combination Approaches as Front-Line Therapy 🎙️ Alessio Cortellini OncoAlert ASCO EGFR Resisters meetings.asco.org/2025-asco-annu…

One of my favorite parts of the ASCO annual meeting— our panel meeting to write the official living guidelines for non-small cell lung cancer ✍️ ascopubs.org/nsclc-da-livin… #ASCO25

A GREAT DAY 2⃣ of #ASCO25 Thanks to the Hard Working ASCO staff for all they do to make this possible‼️ Todays Stats from #MEDTRACK ⚕️are as follows: my.medical.watch/oncoalert/hash… These are brought to you by OncoAlert 🚨and Medical.watch THANK YOU ALL FOR THE AMAZING